» Articles » PMID: 31835700

A Hierarchical Machine Learning Model to Discover Gleason Grade-Specific Biomarkers in Prostate Cancer

Overview
Specialty Radiology
Date 2019 Dec 15
PMID 31835700
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background:One of the most common cancers that affect North American men and men worldwide is prostate cancer. The Gleason score is a pathological grading system to examine the potential aggressiveness of the disease in the prostate tissue. Advancements in computing and next-generation sequencing technology now allow us to study the genomic profiles of patients in association with their different Gleason scores more accurately and effectively. (2) Methods: In this study, we used a novel machine learning method to analyse gene expression of prostate tumours with different Gleason scores, and identify potential genetic biomarkers for each Gleason group. We obtained a publicly-available RNA-Seq dataset of a cohort of 104 prostate cancer patients from the National Center for Biotechnology Information's (NCBI) Gene Expression Omnibus (GEO) repository, and categorised patients based on their Gleason scores to create a hierarchy of disease progression. A hierarchical model with standard classifiers in different Gleason groups, also known as , was developed to identify and predict nodes based on their mRNA or gene expression. In each node, patient samples were analysed via class imbalance and hybrid feature selection techniques to build the prediction model. The outcome from analysis of each node was a set of genes that could differentiate each Gleason group from the remaining groups. To validate the proposed method, the set of identified genes were used to classify a second dataset of 499 prostate cancer patients collected from cBioportal. (3) Results: The overall accuracy of applying this novel method to the first dataset was 93.3%; the method was further validated to have 87% accuracy using the second dataset. This method also identified genes that were not previously reported as potential biomarkers for specific Gleason groups. In particular, was identified as a potential biomarker for Gleason score 4 + 3 = 7, and for Gleason score 6. (4) Insight: Previous reports show that the genes predicted by this newly proposed method strongly correlate with prostate cancer development and progression. Furthermore, pathway analysis shows that both and share similar protein interaction pathways, the JAK/STAT signaling process.

Citing Articles

Machine learning discrimination of Gleason scores below GG3 and above GG4 for HSPC patients diagnosis.

Zhu B, Dai L, Wang H, Zhang K, Zhang C, Wang Y Sci Rep. 2024; 14(1):25641.

PMID: 39465343 PMC: 11514210. DOI: 10.1038/s41598-024-77033-1.


Learning from Imbalanced Data: Integration of Advanced Resampling Techniques and Machine Learning Models for Enhanced Cancer Diagnosis and Prognosis.

Gurcan F, Soylu A Cancers (Basel). 2024; 16(19).

PMID: 39410036 PMC: 11476323. DOI: 10.3390/cancers16193417.


Evaluating Inflammatory Bowel Disease-Related Quality of Life Using an Interpretable Machine Learning Approach: A Multicenter Study in China.

Zhen J, Liu C, Zhang J, Liao F, Xie H, Tan C J Inflamm Res. 2024; 17:5271-5283.

PMID: 39139580 PMC: 11321795. DOI: 10.2147/JIR.S470197.


LncRNA LNC-565686 Promotes Proliferation of Prostate Cancer by Inhibiting Apoptosis through Stabilizing SND1.

Qin X, Zhong J, Wang L, Chen Z, Liu X Biomedicines. 2023; 11(10).

PMID: 37893001 PMC: 10603871. DOI: 10.3390/biomedicines11102627.


The Olfaction Ability of Medical Detection Canine to Detect Prostate Cancer From Urine Samples: Progress Captured in Systematic Review and Meta-Analysis.

Mirsya Warli S, Firsty N, Velaro A, Tala Z World J Oncol. 2023; 14(5):358-370.

PMID: 37869239 PMC: 10588501. DOI: 10.14740/wjon1635.


References
1.
Shuai K . Regulation of cytokine signaling pathways by PIAS proteins. Cell Res. 2006; 16(2):196-202. DOI: 10.1038/sj.cr.7310027. View

2.
Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L . Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res. 2005; 11(16):5863-8. DOI: 10.1158/1078-0432.CCR-05-0562. View

3.
Gospodarowicz M, Benedet L, HUTTER R, Fleming I, Henson D, Sobin L . History and international developments in cancer staging. Cancer Prev Control. 1999; 2(6):262-8. View

4.
Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Bottai G, Stampfer M . DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist. 2013; 18(10):1063-73. PMC: 3805146. DOI: 10.1634/theoncologist.2013-0163. View

5.
Trapnell C, Pachter L, Salzberg S . TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009; 25(9):1105-11. PMC: 2672628. DOI: 10.1093/bioinformatics/btp120. View